2022
DOI: 10.33667/2078-5631-2022-8-35-40
|View full text |Cite
|
Sign up to set email alerts
|

Selective inhibition of JAK1 in treatment of atopic dermatitis: Prescription features and experience with upadacitinib

Abstract: Therapy of moderate-to-severe atopic dermatitis (AD) is associated with a number of diffculties due to the propensity of the disease to a chronic relapsing course, the tendency to develop in childhood and young age. However, a new selective JAK1 inhibitor, which suppresses cytokineinduced inflammation in the skin, has been added to the arsenal of AD systemic therapy.Objective. To evaluate the effcacy, antipruritic activity, impact on quality of life, levels of anxiety and depression, and safety of upadacitinib … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 17 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?